AstraZeneca, breast cancer

US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
Smithsonian Magazine on MSN13h
FDA Bans Red Dye No. 3 From Food, Beverages and Ingested Drugs, Citing Link to Cancer in Lab Rats
After decades of debate, the Food and Drug Administration (FDA) has announced a ban on Red Dye No. 3, a synthetic food ...
FDA bans red food dye due to potential cancer risk
The U.S. Food and Drug Administration has officially banned red dye — called Red 3, or Erythrosine — from foods, dietary ...
IJR2d
FDA Bans Cancer-Linked Food Dye Ahead Of RFK Jr’s Confirmation Hearing
The Food and Drug Administration (FDA) announced Wednesday it will ban Red No. 3, a common artificial food dye linked ...
Food and Drug Administration moves to ban Red 3, citing concern over cancer in some animals
The FDA announced this week it had decided to revoke Red 3's authorization to be added to foods, over concerns about how the ...
Health on MSN1d
FDA Bans Red Dye No. 3 in Food—Over 30 Years After It Was Linked to Cancer in Rats
The FDA has banned red dye No. 3 in food and ingested drugs, the agency announced. But what exactly is red dye No. 3, and why ...
FDA bans Red 3, artificial food dye linked to cancer in lab animals
The Food and Drug Administration announced Wednesday it was banning Red 3 dye from food and beverages in the U.S. over its ...
How food brands and drugmakers are responding to FDA's ban of food dye Red 3
Companies say they are working to update their products to comply with the Food and Drug Administration's decision Wednesday to ban the artificial food dye Red 3, after the agency said it was revoking ...
Latest Medicare price drug negotiations includes Ozempic, Wegovy
Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in ...
abcnews41d
FDA bans Red 3 dye in food, drink and medicine due to cancer risk
Already banned in cosmetics and topical medicines since 1990, the Food and Drug Administration announced on Wednesday that ...
FDA bans Red 3 food dye, citing cancer risk
The FDA has banned Red 3, a dye used in foods like candies and snack cakes, citing cancer risks observed in lab rats.
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRASG12C inhibitor Lumakras as part of a ...